ACARIX AB, WKN: A2DJR2, ISIN: SE0009268717 ▻ Aktueller Aktienkurs, Charts , News, Stammdaten anzeigen.

ACARIX AB (PUBL) : News, information and stories for ACARIX AB (PUBL) | Deutsche Boerse AG: 7AC | Deutsche Boerse AG

no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Tuesday 11 May 2021. Further informationCopies of accounts, audit report, complete proposals including the complete proposed new articles of association, proxy forms, forms for advance voting and other documents that shall be available in accordance with the Swedish Companies Act are available at the Company at Jungmansgatan 12, 211 19 in Malmö and at the Company’s website www.acarix.com, at least three (3 1 dag sedan · STOCKHOLM (Nyhetsbyrån Direkt) Diagnostikbolaget Acarix styrelseledamot Ulf Rosén fortsätter att köpa aktier i bolaget och har senast i torsdags förra veckan förvärvat 322.000 aktier till kursen 1:55 kronor. Affärens värde uppgår således till 0,5 miljoner kronor. Det framgår av Finansinspektionens insynsregister.

Acarix news

Nasdaq First North GM Sweden (SE). News News. Acarix is a Swedish MedTech company marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to Ausschluss KHK bei Patienten mit stabilem Brustschmerz. Das CADScor®️ System kann unterstützend zu Beginn der diagnostischen Abklärung eingesetzt Acarix is commercialising an innovative analytical medical device to rule-out of significant coronary artery disease. Acarix_website.png. READ MORE View live ACARIX AB chart to track its stock's price action. Find market predictions, ACARIX financials and market news.

2021 02 18. Acarix presents the CADScor® System at “Stuttgarter Hausärztetag” – the GP congress of the German federal state of Baden-Württemberg. Acarix announce final outcome in oversubscribed rights issue Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of86,156,738 shares with preferential rights for the Company's existing shareholders, which wasresolved by Get the latest Acarix AB (ACARIX.ST) stock news and headlines to help you in your trading and investing decisions.

Videos & News. Information & Documents. Issuer: Acarix AB. Chairman: Dr. Werner Braun. CEO: Per Persson. Subscription period: 2019-10-08 - 2019-10-25.

ACARIX | Complete Acarix AB stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Acarix announce final outcome in oversubscribed rights issue.

Acarix AB to seek new CEO. Acarix AB (publ) ("Acarix") announced today that CEO Søren Rysholt Christiansen has resigned on 6 Nov. 2017, with the effect to leave the company at the end of February 2018 latest. The Board has begun a search for Mr. Christiansen's successor.

2021 — Acarix AB Pressmeddelande. Positiva prognostiska långtidsdata från Dan-NICAD 1-studien publiceras i European Heart Journal Digital Health Videos & News. Information & Documents. Issuer: Acarix AB. Chairman: Dr. Werner Braun. CEO: Per Persson. Subscription period: 2019-10-08 - 2019-10-25. 22 nov.

See Recommendation. Candlesticks. Short term. Medium term. Latest Acarix AB (ACARIX:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Get today's Acarix A/S stock price and latest ACARIX news as well as Acarix real- time stock quotes, technical analysis, full financials and more. News | Cardiac Diagnostics | August 27, 2018 August 27, 2018 — Acarix AB's ultra-sensitive acoustic CADScor System for coronary artery disease risk Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.
Anmälan till socialtjänsten

Acarix is a medical technology company aiming to streamline and facilitate the News. There is no feed to display at the moment.

ACARIX AB (PUBL) : News, information and stories for ACARIX AB (PUBL) | Nasdaq Stockholm: ACARIX | Nasdaq Stockholm Køb Acarix AB (ACARIX) aktien. Hos Nordnet kan du handle fra 0 kr. i kurtage.
Swedbank personkonto eller bankkonto

nar kan man ta ut de 10 pappadagarna
föreläsning kalmar stress
testamente mall enskild egendom
kommuner i skåne
bra arbetsminne adhd
kolla konkurs företag

2021-04-12

Acarix AB (“Acarix” or the “Company”) has completed the new share issue of a maximum of 86,156,738 shares with preferential rights for the Company’s existing shareholders, which was resolved by the extra general meeting on 11 August 2020 (the “Rights Issue”). Acarix has announced that the FDA is reviewing a de novo 510 (k) application for its innovative CADScor cardiac diagnostic device. This is important news as it could mean that Acarix might enter the US market by 2021 – although it will need marketing alliances and good reimbursement. The Extraordinary General Meeting of Acarix AB ("Acarix" or the "Company") resolved on 11 August 2020, subsequent to the board of directors resolution on 15 July 2020, to approve the board's The board of directors of Acarix AB (“Acarix” or the “Company”) has prepared a supplement to the prospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarix which was approved by the Swedish Financial Supervisory Authority (Sw.

Mats lindén traste
carbohydrate research

Academedia · Acando · Acap Invest · Acarix · Acast · Accent Equity · Acconeer Fake news · Falcon Funds · Fallskärm · FAM · Fannie Mae · Fantasma Games

The results were presented at the American College of Cardiology 2017 Annual Scientific Meeting held in Washington on 17-19 March 2017 and showed that the handheld CADScor System rules out CAD […] Company profile page for Acarix AB including stock price, company news, press releases, executives, board members, and contact information Stock analysis for Acarix AB (ACARIX:FN Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 2020-03-12 2020-09-03 Acarix AB to seek new CEO. Acarix AB (publ) ("Acarix") announced today that CEO Søren Rysholt Christiansen has resigned on 6 Nov. 2017, with the effect to leave the company at the end of February 2018 latest.

Q4-report, with exiting news-flow in 2021 https://www.redeye.se/research/804893/acarix-intervju-med-vd-per-persson-video-2?utm_sourc

The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an ACARIX BTA 1 - Acarix AB Share News. SEK0.926 0.0 0.0% Last Trade - 01/10/20. Sector Healthcare RiskRating.

Redeye gives a brief comment on today's news that the last patient has been recruited to the Acarix fluctue dans un canal haussier. Un développement positif poursuivant le canal haussier est indiqué. L'action a marginalement franchi la résistance à 13 jan. 2021 — Acarix AB (publ) meddelade idag positiva preliminära data från den undersökande SEISMO-studien som görs med modifierade CADScor. ®.